CAS 75747-14-7 | 17-AAG | CAS Number 75747-14-7

Title	Journal
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics 20150501
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.	Clinical cancer research : an official journal of the American Association for Cancer Research 20141115
Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.	European journal of medicinal chemistry 20141006
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.	Clinical cancer research : an official journal of the American Association for Cancer Research 20131101
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.	Pancreas 20130401
Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.	International journal of oncology 20130201
Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.	Molecular pharmaceutics 20121105
Increased expression of heat shock protein 90 under chemical hypoxic conditions protects cardiomyocytes against injury induced by serum and glucose deprivation.	International journal of molecular medicine 20121101
Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.	Journal of controlled release : official journal of the Controlled Release Society 20121010
HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.	Journal of cancer research and clinical oncology 20121001
17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells.	Archives of virology 20121001
Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.	Molecular cancer therapeutics 20121001
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research 20120915
EC144 is a potent inhibitor of the heat shock protein 90.	Journal of medicinal chemistry 20120913
Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.	The Journal of surgical research 20120701
17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.	International journal of oncology 20120701
Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.	Biochemical pharmacology 20120701
Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.	European journal of medicinal chemistry 20120701
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research 20120701
17-AAG mediated targeting of Hsp90 limits tert activity in peritoneal sarcoma related malignant ascites by downregulating cyclin D1 during cell cycle entry.	Experimental oncology 20120701
Inhibition of the mTORC2 and chaperone pathways to treat leukemia.	Blood 20120621
Hsp90 regulates O-linked β-N-acetylglucosamine transferase: a novel mechanism of modulation of protein O-linked β-N-acetylglucosamine modification in endothelial cells.	American journal of physiology. Cell physiology 20120615
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.	Blood 20120614
Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells.	Molecular carcinogenesis 20120601
Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.	Endocrine-related cancer 20120601
Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.	Colloids and surfaces. B, Biointerfaces 20120601
Novel molecular targeted therapies for refractory thyroid cancer.	Head & neck 20120501
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.	Leukemia & lymphoma 20120501
Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.	International journal of oncology 20120501
Fluorescent protein-labeled glucocorticoid receptor alpha isoform trafficking in cultured human trabecular meshwork cells.	Investigative ophthalmology & visual science 20120501
Hsp90 interacts specifically with viral RNA and differentially regulates replication initiation of Bamboo mosaic virus and associated satellite RNA.	PLoS pathogens 20120501
Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.	Biochemical pharmacology 20120415
NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.	Biochemical pharmacology 20120415
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.	Cancer chemotherapy and pharmacology 20120401
SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis.	Biochimica et biophysica acta 20120401
Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C.	Molecular bioSystems 20120401
Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.	Clinical cancer research : an official journal of the American Association for Cancer Research 20120401
Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.	Molecular cancer therapeutics 20120301
Identification of HSP90 as a new GABARAPL1 (GEC1)-interacting protein.	Biochimie 20120301
Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.	Journal of cancer research and clinical oncology 20120301
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.	Investigational new drugs 20120201
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.	Gynecologic oncology 20120201
A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.	Breast cancer research and treatment 20120201
Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.	Biochemical pharmacology 20120201
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.	Molecular cancer therapeutics 20120201
Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress.	Free radical biology & medicine 20120115
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.	Cancer chemotherapy and pharmacology 20120101
Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.	DNA and cell biology 20120101
In vitro drug treatments reduce the deleterious effects of aggregates containing polyAla expanded PHOX2B proteins.	Neurobiology of disease 20120101
Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus.	PloS one 20120101
The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila.	PloS one 20120101
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.	BMC biology 20120101
Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.	BMC research notes 20120101
The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.	Biological & pharmaceutical bulletin 20120101
Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells.	The Journal of toxicological sciences 20120101
The role of hypoxia inducible factor-1α in the increased MMP-2 and MMP-9 production by human monocytes exposed to nickel nanoparticles.	Nanotoxicology 20111201
Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells.	Molecular and cellular biochemistry 20111201
Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.	Molecular cancer research : MCR 20111201
Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable HSP90 inhibitor.	Experimental eye research 20111201
Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.	International journal of pharmaceutics 20111125
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.	Haematologica 20111101
ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.	The Journal of pharmacology and experimental therapeutics 20111101
Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101
Multi-drug delivery to tumor cells via micellar nanocarriers.	International journal of pharmaceutics 20111031
Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.	Journal of medicinal chemistry 20111027
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.	Molecular cancer therapeutics 20111001
Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.	Bioorganic & medicinal chemistry letters 20111001
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.	Cancer cell 20110913
Novel insights into the role of HSP90 in cytoprotection of H2S against chemical hypoxia-induced injury in H9c2 cardiac myocytes.	International journal of molecular medicine 20110901
Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.	Leukemia research 20110901
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.	Cancer research 20110901
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.	Clinical cancer research : an official journal of the American Association for Cancer Research 20110901
Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90.	Bioorganic & medicinal chemistry letters 20110815
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.	Clinical cancer research : an official journal of the American Association for Cancer Research 20110801
A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.	Molecular pharmaceutics 20110801
Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?	Clinical cancer research : an official journal of the American Association for Cancer Research 20110801
[Development of novel agents for multiple myeloma; now and the future].	[Rinsho ketsueki] The Japanese journal of clinical hematology 20110801
Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.	The Journal of biological chemistry 20110715
HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells.	Molecular cancer research : MCR 20110701
Chaxamycins A-D, bioactive ansamycins from a hyper-arid desert Streptomyces sp.	Journal of natural products 20110624
Determination of the volume changes induced by ligand binding to heat shock protein 90 using high-pressure denaturation.	Analytical biochemistry 20110615
Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.	The Journal of biological chemistry 20110603
The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene 20110602
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.	Investigational new drugs 20110601
Hsp90 regulates NADPH oxidase activity and is necessary for superoxide but not hydrogen peroxide production.	Antioxidants & redox signaling 20110601
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.	British journal of haematology 20110601
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.	Cancer chemotherapy and pharmacology 20110501
Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range.	Journal of neurochemistry 20110501
Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.	Cell death & disease 20110501
[Effect of heat shock protein 90 inhibitor 17-dimethylamino-ethylaminogeldanamycin on TNfalpha-mediated apoptosis and TNF-induced NF-kappaB activation].	Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20110501
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research 20110415
In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.	Drug metabolism and disposition: the biological fate of chemicals 20110401
Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices.	Nanomedicine (London, England) 20110401
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.	Molecular pharmacology 20110301
Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.	The Journal of pharmacology and experimental therapeutics 20110301
HSP90 is crucial for regulation of LAT expression in activated T cells.	Molecular immunology 20110301
Identification of aneuploidy-selective antiproliferation compounds.	Cell 20110218
Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.	Molecular and cellular biochemistry 20110201
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.	British journal of haematology 20110201
Tanespimycin as antitumor therapy.	Clinical lymphoma, myeloma & leukemia 20110201
The role of heat shock protein 90 in the regulation of tumor cell apoptosis.	Bulletin of experimental biology and medicine 20110201
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.	Blood 20110127
17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy.	Neurobiology of disease 20110101
Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells.	Journal of andrology 20110101
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.	Neoplasia (New York, N.Y.) 20110101
Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.	PloS one 20110101
High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.	PloS one 20110101
Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death.	Methods in molecular biology (Clifton, N.J.) 20110101
SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.	Bioscience, biotechnology, and biochemistry 20110101
Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.	Nutrition and cancer 20110101
[Heat shock protein 90--modulator of TNFalpha-induced apoptosis of Jurkat tumor cells].	Vestnik Rossiiskoi akademii meditsinskikh nauk 20110101
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.	Molecular cancer 20110101
Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.	PloS one 20110101
Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct.	PloS one 20110101
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.	The Journal of biological chemistry 20101217
N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.	Bioorganic & medicinal chemistry letters 20101215
Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP.	American journal of physiology. Renal physiology 20101201
Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.	Proteomics 20101201
Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.	Blood 20101125
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120
Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90).	Human molecular genetics 20101115
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.	British journal of cancer 20101109
Identification of a novel HSP70-binding cochaperone critical to HSP90-mediated activation of small serine/threonine kinase.	The Journal of biological chemistry 20101105
Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.	Cancer research 20101101
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.	Bioorganic & medicinal chemistry letters 20101101
Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma.	Leukemia 20101001
The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.	British journal of haematology 20101001
Protection of oligodendrocyte precursor cells by low doses of HSP90 inhibitors in cell culture.	Experimental neurology 20100901
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.	Endocrine-related cancer 20100901
Inhibition of heat-shock protein 90 reduces Ebola virus replication.	Antiviral research 20100801
Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.	Experimental eye research 20100801
Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.	British journal of haematology 20100801
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.	British journal of haematology 20100801
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.	Clinical cancer research : an official journal of the American Association for Cancer Research 20100715
RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.	The Journal of clinical endocrinology and metabolism 20100701
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.	Oncotarget 20100701
Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker.	Oncotarget 20100701
A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.	Biochemical pharmacology 20100601
Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.	Free radical biology & medicine 20100601
HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.	Oncology reports 20100601
Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.	Cardiovascular research 20100501
Hsp90 inhibitors: a potential treatment for latent EBV infection?	Cell cycle (Georgetown, Tex.) 20100501
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.	Molecular cancer therapeutics 20100501
Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.	Circulation research 20100430
Hsp90 directly modulates the spatial distribution of AF9/MLLT3 and affects target gene expression.	The Journal of biological chemistry 20100416
Targeting the 90 kDa heat shock protein improves photodynamic therapy.	Cancer letters 20100328
Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132.	Antiviral chemistry & chemotherapy 20100309
17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1alpha and ILK in mouse RPE cells.	Molecular biology reports 20100301
BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.	International journal of cancer 20100301
BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.	International journal of cancer 20100301
[Management of metastatic HER2-positive breast cancer: present and future].	Bulletin du cancer 20100301
Hsp90-functionalized polypyrrole nanotube FET sensor for anti-cancer agent detection.	Biosensors & bioelectronics 20100215
Heat shock protein 90: inhibitors in clinical trials.	Journal of medicinal chemistry 20100114
The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.	The Journal of neuroscience : the official journal of the Society for Neuroscience 20100113
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.	Journal of neurosurgery 20100101
17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy.	PloS one 20100101
Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells.	Molecular cancer 20100101
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells.	Journal of biomedical science 20100101
Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.	PloS one 20100101
17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.	BMC cancer 20100101
Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.	BMC medical genomics 20100101
17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.	Breast cancer research : BCR 20100101
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.	Molecular cancer therapeutics 20091201
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201
Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.	British journal of cancer 20091103
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.	Magnetic resonance in medicine 20091101
[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].	Rinsho shinkeigaku = Clinical neurology 20091101
Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.	Cancer letters 20091018
Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.	Journal of immunology (Baltimore, Md. : 1950) 20091001
Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.	Expert opinion on investigational drugs 20090901
Met amplification and HSP90 inhibitors.	Cell cycle (Georgetown, Tex.) 20090901
Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.	Cancer 20090815
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.	Molecular cancer therapeutics 20090801
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.	Molecular cancer therapeutics 20090801
Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death.	Molecular cancer therapeutics 20090801
Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.	Journal of medicinal chemistry 20090723
Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma.	Biochemical pharmacology 20090715
Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells.	Cancer chemotherapy and pharmacology 20090701
Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.	The Journal of pharmacology and experimental therapeutics 20090701
Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.	Cell cycle (Georgetown, Tex.) 20090701
Potent triazolothione inhibitor of heat-shock protein-90.	Chemical biology & drug design 20090701
Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.	Expert opinion on investigational drugs 20090601
Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.	Anticancer research 20090601
Potent cytotoxic C-11 modified geldanamycin analogues.	Journal of medicinal chemistry 20090528
Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.	Cancer research 20090501
Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.	Journal of medicinal chemistry 20090423
Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.	Clinical cancer research : an official journal of the American Association for Cancer Research 20090415
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.	Neuro-oncology 20090401
A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats.	Journal of pharmaceutical sciences 20090401
High cytotoxic sensitivity of the oligodendrocyte precursor cells to HSP90 inhibitors in cell cultures.	Experimental neurology 20090401
Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.	Journal of medicinal chemistry 20090326
Discovery and development of heat shock protein 90 inhibitors.	Bioorganic & medicinal chemistry 20090315
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.	Cancer research 20090301
The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.	British journal of haematology 20090201
Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.	International journal of oncology 20090201
An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo.	Annals of nuclear medicine 20090201
Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.	British journal of cancer 20090127
VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.	International journal of pharmaceutics 20090105
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.	Molecular pharmacology 20090101
Effectiveness of 17DMAG, a geldanamycin derivative, in murine acute myeloid leukemia.	Acta haematologica 20090101
COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70.	PloS one 20090101
Inhibition and function of heat shock proteins 70 and 90.	Current topics in medicinal chemistry 20090101
Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.	Journal of pharmaceutical sciences 20081201
Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.	Acta pharmacologica Sinica 20081101
Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation.	Cancer prevention research (Philadelphia, Pa.) 20081101
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research 20081015
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.	Cancer chemotherapy and pharmacology 20081001
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.	Blood 20081001
Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.	Journal of medicinal chemistry 20080925
Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.	Cell cycle (Georgetown, Tex.) 20080915
Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.	Clinical cancer research : an official journal of the American Association for Cancer Research 20080915
P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.	Cancer research 20080915
Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.	Cancer cell 20080909
The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.	Cancer letters 20080908
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.	Blood 20080901
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.	Molecular cancer therapeutics 20080901
Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury.	American journal of physiology. Renal physiology 20080801
Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.	Anti-cancer drugs 20080801
Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.	Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080801
Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin.	International journal of radiation oncology, biology, physics 20080701
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.	Cancer research 20080615
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.	Investigative ophthalmology & visual science 20080601
RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.	Leukemia 20080601
Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.	Cancer science 20080601
Arsenic trioxide decreases AKT protein in a caspase-dependent manner.	Molecular cancer therapeutics 20080601
Chaperone-dependent stabilization and degradation of p53 mutants.	Oncogene 20080529
IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.	Cancer chemotherapy and pharmacology 20080501
Dopamine-induced toxicity is synergistically potentiated by simultaneous HSP-90 and Akt inhibition in oligodendrocyte progenitors.	Journal of neurochemistry 20080501
Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.	British journal of haematology 20080501
Geldanamycin enhances hepatocyte growth factor stimulation of eNOS phosphorylation in endothelial cells.	European journal of pharmacology 20080317
Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.	Bioorganic & medicinal chemistry letters 20080301
Prevention of chemotherapy-induced alopecia in rodent models.	Cell stress & chaperones 20080301
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.	Journal of medicinal chemistry 20080124
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.	Cancer research 20080115
Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.	Angewandte Chemie (International ed. in English) 20080101
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.	Breast cancer research : BCR 20080101
A highly invasive human glioblastoma pre-clinical model for testing therapeutics.	Journal of translational medicine 20080101
Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin.	Molecular pharmacology 20071201
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.	British journal of haematology 20071201
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071201
SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.	Cancer biology & therapy 20071201
Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.	Clinical cancer research : an official journal of the American Association for Cancer Research 20071101
Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis.	American journal of respiratory and critical care medicine 20071001
Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.	The Journal of urology 20071001
The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.	The Journal of pathology 20071001
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.	Cell death and differentiation 20070901
The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.	Anti-cancer drugs 20070901
Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070701
Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.	Journal of medicinal chemistry 20070614
Geldanamycin derivatives and neuroprotective effect on cultured P19-derived neurons.	Bioorganic & medicinal chemistry letters 20070515
Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.	Cancer research 20070515
Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes.	The Journal of biological chemistry 20070420
Inhibition of heat shock protein-90 modulates multiple functions required for survival of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells.	International journal of cancer 20070415
Proteomic analysis of waldenstrom macroglobulinemia.	Cancer research 20070415
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.	Clinical cancer research : an official journal of the American Association for Cancer Research 20070401
Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling.	Clinical cancer research : an official journal of the American Association for Cancer Research 20070401
Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.	Cancer research 20070401
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.	Clinical cancer research : an official journal of the American Association for Cancer Research 20070315
Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.	Leukemia 20070301
Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.	Clinical cancer research : an official journal of the American Association for Cancer Research 20070301
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.	Molecular cancer therapeutics 20070301
Multiple myeloma therapies.	Nature reviews. Drug discovery 20070301
Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.	International journal of cancer 20070215
Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.	Cancer research 20070215
Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prematurity.	Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20070201
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.	British journal of haematology 20070201
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.	IDrugs : the investigational drugs journal 20070201
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.	Molecular cancer therapeutics 20070201
[Integrated molecular medicine for neuronal and neoplastic disorders].	Seikagaku. The Journal of Japanese Biochemical Society 20070201
RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.	Molecular cell 20070126
Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.	Genes & development 20070115
The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.	The Journal of biological chemistry 20070105
Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications.	Drug metabolism and disposition: the biological fate of chemicals 20070101
Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy.	Neuro-degenerative diseases 20070101
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.	PloS one 20070101
Mechanisms of Legionella pneumophila-induced interleukin-8 expression in human lung epithelial cells.	BMC microbiology 20070101
Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.	Current medicinal chemistry 20070101
Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.	Journal of medicinal chemistry 20061228
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.	Journal of neurochemistry 20061201
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.	Experimental hematology 20061201
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.	Endocrine-related cancer 20061201
Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.	Cancer research 20061115
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.	Clinical cancer research : an official journal of the American Association for Cancer Research 20061115
Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis.	Neurobiology of disease 20061101
MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.	Molecular cancer research : MCR 20061101
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.	Cancer research 20060915
Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.	Cell death and differentiation 20060901
Synthesis of a red-shifted fluorescence polarization probe for Hsp90.	Bioorganic & medicinal chemistry letters 20060901
Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.	Journal of molecular medicine (Berlin, Germany) 20060801
Current and future management of GIST.	Clinical advances in hematology & oncology : H&O 20060801
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.	Journal of medicinal chemistry 20060727
17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation.	Oncogene 20060713
Synthesis of Hsp90 dimerization modulators.	Bioorganic & medicinal chemistry letters 20060701
Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.	Leukemia & lymphoma 20060701
[Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line].	Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?	International journal of cancer 20060601
Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid.	The Journal of clinical endocrinology and metabolism 20060601
Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.	Biochemistry 20060502
The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.	Leukemia research 20060501
4-Amino derivatives of the Hsp90 inhibitor CCT018159.	Bioorganic & medicinal chemistry letters 20060501
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.	Molecular carcinogenesis 20060501
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.	Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20060501
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.	Molecular cancer therapeutics 20060501
Identification of new biomarkers for clinical trials of Hsp90 inhibitors.	Molecular cancer therapeutics 20060501
Identification of genes involved in the sensitivity to antitumour drug 17-allylamino,17-demethoxygeldanamycin (17AAG).	Molecular bioSystems 20060501
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.	Immunology letters 20060415
Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.	Cancer research 20060415
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.	Leukemia 20060401
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.	Clinical cancer research : an official journal of the American Association for Cancer Research 20060401
Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.	Journal of cancer research and clinical oncology 20060301
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.	Molecular cancer therapeutics 20060301
Antimyeloma activity of heat shock protein-90 inhibition.	Blood 20060201
Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta.	Investigative ophthalmology & visual science 20060201
17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.	Cancer research 20060115
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.	Clinical cancer research : an official journal of the American Association for Cancer Research 20060115
Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.	Molecular carcinogenesis 20060101
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells.	Molecular cancer therapeutics 20060101
Hsp90 inhibitors in the clinic.	Handbook of experimental pharmacology 20060101
Stimulation of proteasome activity as a therapeutic target in schizophrenia: possible usefulness of 17-allylamino-demethoxygeldanamycin.	Medical hypotheses 20060101
Effect of the Hsp90 modulators on the heat-shock response in eukaryotic cells.	Folia microbiologica 20060101
Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.	Anticancer research 20060101
In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.	Anticancer research 20060101
Inhibitors of the HSP90 molecular chaperone: current status.	Advances in cancer research 20060101
In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin in rats.	Toxicology in vitro : an international journal published in association with BIBRA 20051201
Structure-based discovery of a new class of Hsp90 inhibitors.	Bioorganic & medicinal chemistry letters 20051201
17-AAG: mechanisms of antitumour activity.	Expert opinion on investigational drugs 20051201
Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.	Cancer research 20051201
Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.	Cancer research 20051201
Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.	Cancer science 20051201
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.	Cancer research 20051115
Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.	Cancer research 20051101
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.	Blood 20051001
In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin using dog liver slices.	Toxicological sciences : an official journal of the Society of Toxicology 20051001
17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.	Nature medicine 20051001
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.	Clinical cancer research : an official journal of the American Association for Cancer Research 20051001
Targeting toxic proteins for turnover.	Nature medicine 20051001
Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.	Leukemia 20050901
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.	Molecular cancer therapeutics 20050901
A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.	Clinical prostate cancer 20050901
Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.	Bioorganic & medicinal chemistry 20050815
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.	Biochemical pharmacology 20050815
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.	Cancer chemotherapy and pharmacology 20050801
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.	Clinical cancer research : an official journal of the American Association for Cancer Research 20050801
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.	Blood 20050701
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.	Leukemia 20050701
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.	Leukemia 20050701
Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism.	Acta biochimica et biophysica Sinica 20050701
Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.	Journal of medicinal chemistry 20050630
Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620
The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.	Cancer research 20050601
Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.	Assay and drug development technologies 20050601
Heat shock proteins and acute leukemias.	Hematology (Amsterdam, Netherlands) 20050601
Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.	Clinical cancer research : an official journal of the American Association for Cancer Research 20050515
Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.	Leukemia 20050501
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.	Clinical cancer research : an official journal of the American Association for Cancer Research 20050501
Rational design of shepherdin, a novel anticancer agent.	Cancer cell 20050501
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.	Molecular pharmacology 20050401
Production of 8-demethylgeldanamycin and 4,5-epoxy-8-demethylgeldanamycin from a recombinant strain of Streptomyces hygroscopicus.	Journal of natural products 20050401
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.	Future oncology (London, England) 20050401
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320
Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.	Cancer chemotherapy and pharmacology 20050301
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.	Pediatric research 20050301
The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells.	Pediatric hematology and oncology 20050301
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.	Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.	Blood 20050215
17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.	Gynecologic oncology 20050201
Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase.	Arteriosclerosis, thrombosis, and vascular biology 20041201
Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells.	The Journal of biological chemistry 20041015
Hsp90: an emerging target for breast cancer therapy.	Anti-cancer drugs 20040801
Altered Hsp90 function in cancer: a unique therapeutic opportunity.	Molecular cancer therapeutics 20040801
[Heat shock protein 90: novel target for cancer therapy].	Ai zheng = Aizheng = Chinese journal of cancer 20040801
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.	Clinical cancer research : an official journal of the American Association for Cancer Research 20040715
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.	Nature biotechnology 20040601
An image worth a thousand lives?	Nature biotechnology 20040601
Therapeutic and diagnostic implications of Hsp90 activation.	Trends in molecular medicine 20040601
17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels.	The Journal of clinical endocrinology and metabolism 20040601
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.	Cancer research 20040515
Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.	Cancer research 20040501
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.	Molecular cancer therapeutics 20040501
Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.	Oncology (Williston Park, N.Y.) 20040501
Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.	Cancer letters 20040408
17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.	Anti-cancer drugs 20040401
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.	Blood 20040201
Altered states: selectively drugging the Hsp90 cancer chaperone.	Trends in molecular medicine 20040201
Protein chaperones as anticancer therapy targets.	Clinical advances in hematology & oncology : H&O 20040201
Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.	Bioorganic & medicinal chemistry letters 20040119
Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.	Molecular pharmacology 20040101
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.	Cancer research 20040101
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.	The Journal of biological chemistry 20031226
Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.	Cancer research 20031215
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.	Cancer research 20031215
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.	Cancer research 20031201
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.	Cancer research 20031201
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.	Journal of the National Cancer Institute 20031105
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.	Clinical cancer research : an official journal of the American Association for Cancer Research 20031015
Overview: translating Hsp90 biology into Hsp90 drugs.	Current cancer drug targets 20031001
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.	Current cancer drug targets 20031001
The clinical applications of heat shock protein inhibitors in cancer - present and future.	Current cancer drug targets 20031001
FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.	Clinical cancer research : an official journal of the American Association for Cancer Research 20031001
Hsp90 as a therapeutic target in prostate cancer.	Seminars in oncology 20031001
Cancer: the rules of attraction.	Nature 20030925
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.	Nature 20030925
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.	Blood 20030901
Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.	Clinical cancer research : an official journal of the American Association for Cancer Research 20030901
Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.	Cancer chemotherapy and pharmacology 20030801
The Hsp90 chaperone complex as a novel target for cancer therapy.	Annals of oncology : official journal of the European Society for Medical Oncology 20030801
Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.	The Journal of biological chemistry 20030704
Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases.	Blood 20030701
Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.	Cancer research 20030615
Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.	Journal of pharmacokinetics and pharmacodynamics 20030601
Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.	Current medicinal chemistry 20030501
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.	Cancer research 20030501
Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.	British journal of haematology 20030501
Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.	Carcinogenesis 20030501
ErbB2 degradation mediated by the co-chaperone protein CHIP.	The Journal of biological chemistry 20030418
17AAG: low target binding affinity and potent cell activity--finding an explanation.	Molecular cancer therapeutics 20030201
Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.	Molecular cancer therapeutics 20030201
Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.	Gene 20030102
[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].	Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20030101
The role of functional and molecular imaging in cancer drug discovery and development.	The British journal of radiology 20030101
Synthetic lethality: killing cancer with cancer.	Journal of the National Cancer Institute 20021120
Challenges of PK/PD measurements in modern drug development.	European journal of cancer (Oxford, England : 1990) 20021101
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.	Cancer research 20021015
Heat shock protein and proteasome targeting agents.	Hematology/oncology clinics of North America 20021001
Heat shock protein inhibitor shows antitumor activity.	Journal of the National Cancer Institute 20020821
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.	Cancer research 20020601
Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.	Clinical cancer research : an official journal of the American Association for Cancer Research 20020501
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.	Clinical cancer research : an official journal of the American Association for Cancer Research 20020501
Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.	Cancer research 20020301
Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis.	Journal of neuroscience research 20020215
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.	Oncogene 20020214
HSP90 as a new therapeutic target for cancer therapy: the story unfolds.	Expert opinion on biological therapy 20020101
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.	Clinical cancer research : an official journal of the American Association for Cancer Research 20010801
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.	Clinical cancer research : an official journal of the American Association for Cancer Research 20010801
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.	Cancer research 20010515
Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.	Cancer research 20010515
Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography.	Journal of chromatography. B, Biomedical sciences and applications 20010505
LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.	Bioorganic & medicinal chemistry letters 20010409
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.	Cancer research 20010401
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.	Cancer chemotherapy and pharmacology 20010401
Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.	British journal of cancer 20010301
Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.	Cancer research 20010301

Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.

International journal of oncology 20130201

Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

Molecular pharmaceutics 20121105

Increased expression of heat shock protein 90 under chemical hypoxic conditions protects cardiomyocytes against injury induced by serum and glucose deprivation.

International journal of molecular medicine 20121101

Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.

Journal of controlled release : official journal of the Controlled Release Society 20121010

HSP90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents.

Journal of cancer research and clinical oncology 20121001

17-allylamino-17-(demethoxy)geldanamycin (17-AAG) is a potent and effective inhibitor of human cytomegalovirus replication in primary fibroblast cells.

Archives of virology 20121001

Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.

Molecular cancer therapeutics 20121001

Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120915

EC144 is a potent inhibitor of the heat shock protein 90.

Journal of medicinal chemistry 20120913

Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.

The Journal of surgical research 20120701

17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.

International journal of oncology 20120701

Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.

Biochemical pharmacology 20120701

Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.

European journal of medicinal chemistry 20120701

Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120701

17-AAG mediated targeting of Hsp90 limits tert activity in peritoneal sarcoma related malignant ascites by downregulating cyclin D1 during cell cycle entry.

Experimental oncology 20120701

Inhibition of the mTORC2 and chaperone pathways to treat leukemia.

Blood 20120621

Hsp90 regulates O-linked β-N-acetylglucosamine transferase: a novel mechanism of modulation of protein O-linked β-N-acetylglucosamine modification in endothelial cells.

American journal of physiology. Cell physiology 20120615

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.

Blood 20120614

Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells.

Molecular carcinogenesis 20120601

Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.

Endocrine-related cancer 20120601

Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.

Colloids and surfaces. B, Biointerfaces 20120601

Novel molecular targeted therapies for refractory thyroid cancer.

Head & neck 20120501

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.

Leukemia & lymphoma 20120501

Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.

International journal of oncology 20120501

Fluorescent protein-labeled glucocorticoid receptor alpha isoform trafficking in cultured human trabecular meshwork cells.

Investigative ophthalmology & visual science 20120501

Hsp90 interacts specifically with viral RNA and differentially regulates replication initiation of Bamboo mosaic virus and associated satellite RNA.

PLoS pathogens 20120501

Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Biochemical pharmacology 20120415

NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.

Biochemical pharmacology 20120415

A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.

Cancer chemotherapy and pharmacology 20120401

SUMO-2/3 conjugates accumulating under heat shock or MG132 treatment result largely from new protein synthesis.

Biochimica et biophysica acta 20120401

Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C.

Molecular bioSystems 20120401

Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120401

Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.

Molecular cancer therapeutics 20120301

Identification of HSP90 as a new GABARAPL1 (GEC1)-interacting protein.

Biochimie 20120301

Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells.

Journal of cancer research and clinical oncology 20120301

A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma.

Investigational new drugs 20120201

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Gynecologic oncology 20120201

A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer.

Breast cancer research and treatment 20120201

Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.

Biochemical pharmacology 20120201

Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.

Molecular cancer therapeutics 20120201

Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress.

Free radical biology & medicine 20120115

In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.

Cancer chemotherapy and pharmacology 20120101

Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines.

DNA and cell biology 20120101

In vitro drug treatments reduce the deleterious effects of aggregates containing polyAla expanded PHOX2B proteins.

Neurobiology of disease 20120101

Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus.

PloS one 20120101

The aggregation and neurotoxicity of TDP-43 and its ALS-associated 25 kDa fragment are differentially affected by molecular chaperones in Drosophila.

PloS one 20120101

Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation.

BMC biology 20120101

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.

BMC research notes 20120101

The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells.

Biological & pharmaceutical bulletin 20120101

Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells.

The Journal of toxicological sciences 20120101

The role of hypoxia inducible factor-1α in the increased MMP-2 and MMP-9 production by human monocytes exposed to nickel nanoparticles.

Nanotoxicology 20111201

Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells.

Molecular and cellular biochemistry 20111201

Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.

Molecular cancer research : MCR 20111201

Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable HSP90 inhibitor.

Experimental eye research 20111201

Synthesis and evaluation of poly(styrene-co-maleic acid) micellar nanocarriers for the delivery of tanespimycin.

International journal of pharmaceutics 20111125

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Haematologica 20111101

ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.

The Journal of pharmacology and experimental therapeutics 20111101

Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20111101

Multi-drug delivery to tumor cells via micellar nanocarriers.

International journal of pharmaceutics 20111031

Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.

Journal of medicinal chemistry 20111027

The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.

Molecular cancer therapeutics 20111001

Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.

Bioorganic & medicinal chemistry letters 20111001

Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.

Cancer cell 20110913

Novel insights into the role of HSP90 in cytoprotection of H2S against chemical hypoxia-induced injury in H9c2 cardiac myocytes.

International journal of molecular medicine 20110901

Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor.

Leukemia research 20110901

Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.

Cancer research 20110901

The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110901

Synthesis and evaluation of biotinylated sansalvamide A analogs and their modulation of Hsp90.

Bioorganic & medicinal chemistry letters 20110815

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Molecular pharmaceutics 20110801

Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

Clinical cancer research : an official journal of the American Association for Cancer Research 20110801

[Development of novel agents for multiple myeloma; now and the future].

[Rinsho ketsueki] The Japanese journal of clinical hematology 20110801

Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1.

The Journal of biological chemistry 20110715

HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells.

Molecular cancer research : MCR 20110701

Chaxamycins A-D, bioactive ansamycins from a hyper-arid desert Streptomyces sp.

Journal of natural products 20110624

Determination of the volume changes induced by ligand binding to heat shock protein 90 using high-pressure denaturation.

Analytical biochemistry 20110615

Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

The Journal of biological chemistry 20110603

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Oncogene 20110602

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Investigational new drugs 20110601

Hsp90 regulates NADPH oxidase activity and is necessary for superoxide but not hydrogen peroxide production.

Antioxidants & redox signaling 20110601

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

British journal of haematology 20110601

Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations.

Cancer chemotherapy and pharmacology 20110501

Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range.

Journal of neurochemistry 20110501

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.

Cell death & disease 20110501

[Effect of heat shock protein 90 inhibitor 17-dimethylamino-ethylaminogeldanamycin on TNfalpha-mediated apoptosis and TNF-induced NF-kappaB activation].

Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20110501

Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20110415

In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.

Drug metabolism and disposition: the biological fate of chemicals 20110401

Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices.

Nanomedicine (London, England) 20110401

A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.

Molecular pharmacology 20110301

Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells.

The Journal of pharmacology and experimental therapeutics 20110301

HSP90 is crucial for regulation of LAT expression in activated T cells.

Molecular immunology 20110301

Identification of aneuploidy-selective antiproliferation compounds.

Cell 20110218

Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.

Molecular and cellular biochemistry 20110201

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.

British journal of haematology 20110201

Tanespimycin as antitumor therapy.

Clinical lymphoma, myeloma & leukemia 20110201

The role of heat shock protein 90 in the regulation of tumor cell apoptosis.

Bulletin of experimental biology and medicine 20110201

The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.

Blood 20110127

17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy.

Neurobiology of disease 20110101

Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells.

Journal of andrology 20110101

Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.

Neoplasia (New York, N.Y.) 20110101

Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma.

PloS one 20110101

High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.

PloS one 20110101

Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death.

Methods in molecular biology (Clifton, N.J.) 20110101

SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.

Bioscience, biotechnology, and biochemistry 20110101

Sulforaphane potentiates the efficacy of 17-allylamino 17-demethoxygeldanamycin against pancreatic cancer through enhanced abrogation of Hsp90 chaperone function.

Nutrition and cancer 20110101

[Heat shock protein 90--modulator of TNFalpha-induced apoptosis of Jurkat tumor cells].

Vestnik Rossiiskoi akademii meditsinskikh nauk 20110101

Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.

Molecular cancer 20110101

Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment.

PloS one 20110101

Assessment of hypoxia inducible factor levels in cancer cell lines upon hypoxic induction using a novel reporter construct.

PloS one 20110101

Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.

The Journal of biological chemistry 20101217

N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors.

Bioorganic & medicinal chemistry letters 20101215

Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP.

American journal of physiology. Renal physiology 20101201

Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.

Proteomics 20101201

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.

Blood 20101125

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101120

Prevention of autosomal dominant retinitis pigmentosa by systemic drug therapy targeting heat shock protein 90 (Hsp90).

Human molecular genetics 20101115

Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.

British journal of cancer 20101109

Identification of a novel HSP70-binding cochaperone critical to HSP90-mediated activation of small serine/threonine kinase.

The Journal of biological chemistry 20101105

Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.

Cancer research 20101101

Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

Bioorganic & medicinal chemistry letters 20101101

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma.

Leukemia 20101001

The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway.

British journal of haematology 20101001

Protection of oligodendrocyte precursor cells by low doses of HSP90 inhibitors in cell culture.

Experimental neurology 20100901

Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.

Endocrine-related cancer 20100901

Inhibition of heat-shock protein 90 reduces Ebola virus replication.

Antiviral research 20100801

Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.

Experimental eye research 20100801

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

British journal of haematology 20100801

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

British journal of haematology 20100801

Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.

Clinical cancer research : an official journal of the American Association for Cancer Research 20100715

RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.

The Journal of clinical endocrinology and metabolism 20100701

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.

Oncotarget 20100701

Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker.

Oncotarget 20100701

A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.

Biochemical pharmacology 20100601

Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs.

Free radical biology & medicine 20100601

HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.

Oncology reports 20100601

Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.

Cardiovascular research 20100501

Hsp90 inhibitors: a potential treatment for latent EBV infection?

Cell cycle (Georgetown, Tex.) 20100501

17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.

Molecular cancer therapeutics 20100501

Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.

Circulation research 20100430

Hsp90 directly modulates the spatial distribution of AF9/MLLT3 and affects target gene expression.

The Journal of biological chemistry 20100416

Targeting the 90 kDa heat shock protein improves photodynamic therapy.

Cancer letters 20100328

Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132.

Antiviral chemistry & chemotherapy 20100309

17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1alpha and ILK in mouse RPE cells.

Molecular biology reports 20100301

BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.

International journal of cancer 20100301

BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance.

International journal of cancer 20100301

[Management of metastatic HER2-positive breast cancer: present and future].

Bulletin du cancer 20100301

Hsp90-functionalized polypyrrole nanotube FET sensor for anti-cancer agent detection.

Biosensors & bioelectronics 20100215

Heat shock protein 90: inhibitors in clinical trials.

Journal of medicinal chemistry 20100114

The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules.

The Journal of neuroscience : the official journal of the Society for Neuroscience 20100113

Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.

Journal of neurosurgery 20100101

17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy.

PloS one 20100101

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells.

Molecular cancer 20100101

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells.

Journal of biomedical science 20100101

Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.

PloS one 20100101

17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells.

BMC cancer 20100101

Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.

BMC medical genomics 20100101

17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2.

Breast cancer research : BCR 20100101

The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.

Molecular cancer therapeutics 20091201

Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.

British journal of cancer 20091103

Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.

Magnetic resonance in medicine 20091101

[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases].

Rinsho shinkeigaku = Clinical neurology 20091101

Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.

Cancer letters 20091018

Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.

Journal of immunology (Baltimore, Md. : 1950) 20091001

Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.

Expert opinion on investigational drugs 20090901

Met amplification and HSP90 inhibitors.

Cell cycle (Georgetown, Tex.) 20090901

Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures.

Cancer 20090815

Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.

Molecular cancer therapeutics 20090801

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

Molecular cancer therapeutics 20090801

Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death.

Molecular cancer therapeutics 20090801

Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents.

Journal of medicinal chemistry 20090723

Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma.

Biochemical pharmacology 20090715

Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells.

Cancer chemotherapy and pharmacology 20090701

Heat shock protein 90 inhibitor induces apoptosis and attenuates activation of hepatic stellate cells.

The Journal of pharmacology and experimental therapeutics 20090701

Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors.

Cell cycle (Georgetown, Tex.) 20090701

Potent triazolothione inhibitor of heat-shock protein-90.

Chemical biology & drug design 20090701

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.

Expert opinion on investigational drugs 20090601

Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.

Anticancer research 20090601

Potent cytotoxic C-11 modified geldanamycin analogues.

Journal of medicinal chemistry 20090528

Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d.

Cancer research 20090501

Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.

Journal of medicinal chemistry 20090423

Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090415

Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.

Neuro-oncology 20090401

A cremophor-free formulation for tanespimycin (17-AAG) using PEO-b-PDLLA micelles: characterization and pharmacokinetics in rats.

Journal of pharmaceutical sciences 20090401

High cytotoxic sensitivity of the oligodendrocyte precursor cells to HSP90 inhibitors in cell cultures.

Experimental neurology 20090401

Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors from genetic engineering of Streptomyces hygroscopicus.

Journal of medicinal chemistry 20090326

Discovery and development of heat shock protein 90 inhibitors.

Bioorganic & medicinal chemistry 20090315

Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.

Cancer research 20090301

The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

British journal of haematology 20090201

Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.

International journal of oncology 20090201

An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo.

Annals of nuclear medicine 20090201

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.

British journal of cancer 20090127

VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.

International journal of pharmaceutics 20090105

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Molecular pharmacology 20090101

Effectiveness of 17DMAG, a geldanamycin derivative, in murine acute myeloid leukemia.

Acta haematologica 20090101

COMMD1 Promotes pVHL and O2-Independent Proteolysis of HIF-1alpha via HSP90/70.

PloS one 20090101

Inhibition and function of heat shock proteins 70 and 90.

Current topics in medicinal chemistry 20090101

Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation.

Journal of pharmaceutical sciences 20081201

Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells.

Acta pharmacologica Sinica 20081101

Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation.

Cancer prevention research (Philadelphia, Pa.) 20081101

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20081015

An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.

Cancer chemotherapy and pharmacology 20081001

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.

Blood 20081001

Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.

Journal of medicinal chemistry 20080925

Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.

Cell cycle (Georgetown, Tex.) 20080915

Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

Clinical cancer research : an official journal of the American Association for Cancer Research 20080915

P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

Cancer research 20080915

Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis.

Cancer cell 20080909

The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells.

Cancer letters 20080908

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

Blood 20080901

Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.

Molecular cancer therapeutics 20080901

Heat shock protein 90-binding agents protect renal cells from oxidative stress and reduce kidney ischemia-reperfusion injury.

American journal of physiology. Renal physiology 20080801

Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.

Anti-cancer drugs 20080801

Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080801

Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin.

International journal of radiation oncology, biology, physics 20080701

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.

Cancer research 20080615

17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.

Investigative ophthalmology & visual science 20080601

RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.

Leukemia 20080601

Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.

Cancer science 20080601

Arsenic trioxide decreases AKT protein in a caspase-dependent manner.

Molecular cancer therapeutics 20080601

Chaperone-dependent stabilization and degradation of p53 mutants.

Oncogene 20080529

IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.

Cancer chemotherapy and pharmacology 20080501

Dopamine-induced toxicity is synergistically potentiated by simultaneous HSP-90 and Akt inhibition in oligodendrocyte progenitors.

Journal of neurochemistry 20080501

Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.

British journal of haematology 20080501

Geldanamycin enhances hepatocyte growth factor stimulation of eNOS phosphorylation in endothelial cells.

European journal of pharmacology 20080317

Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.

Bioorganic & medicinal chemistry letters 20080301

Prevention of chemotherapy-induced alopecia in rodent models.

Cell stress & chaperones 20080301

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Journal of medicinal chemistry 20080124

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Cancer research 20080115

Divergent synthesis of a pochonin library targeting HSP90 and in vivo efficacy of an identified inhibitor.

Angewandte Chemie (International ed. in English) 20080101

Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.

Breast cancer research : BCR 20080101

A highly invasive human glioblastoma pre-clinical model for testing therapeutics.

Journal of translational medicine 20080101

Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin.

Molecular pharmacology 20071201

Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.

British journal of haematology 20071201

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071201

SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.

Cancer biology & therapy 20071201

Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.

Clinical cancer research : an official journal of the American Association for Cancer Research 20071101

Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis.

American journal of respiratory and critical care medicine 20071001

Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model.

The Journal of urology 20071001

The heat-shock protein 90 inhibitor, geldanamycin, induces apoptotic cell death in Epstein-Barr virus-positive NK/T-cell lymphoma by Akt down-regulation.

The Journal of pathology 20071001

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.

Cell death and differentiation 20070901

The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo.

Anti-cancer drugs 20070901

Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070701

Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.

Journal of medicinal chemistry 20070614

Geldanamycin derivatives and neuroprotective effect on cultured P19-derived neurons.

Bioorganic & medicinal chemistry letters 20070515

Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.

Cancer research 20070515

Regulation of death-associated protein kinase. Stabilization by HSP90 heterocomplexes.

The Journal of biological chemistry 20070420

Inhibition of heat shock protein-90 modulates multiple functions required for survival of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells.

International journal of cancer 20070415

Proteomic analysis of waldenstrom macroglobulinemia.

Cancer research 20070415

Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070401

Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070401

Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

Cancer research 20070401

Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070315

Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.

Leukemia 20070301

Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070301

Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Molecular cancer therapeutics 20070301

Multiple myeloma therapies.

Nature reviews. Drug discovery 20070301

Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.

International journal of cancer 20070215

Heat shock protein 90 and ErbB2 in the cardiac response to doxorubicin injury.

Cancer research 20070215

Geldanamycin treatment reduces neovascularization in a mouse model of retinopathy of prematurity.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20070201

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

British journal of haematology 20070201

American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.

IDrugs : the investigational drugs journal 20070201

17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.

Molecular cancer therapeutics 20070201

[Integrated molecular medicine for neuronal and neoplastic disorders].

Seikagaku. The Journal of Japanese Biochemical Society 20070201

RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.

Molecular cell 20070126

Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance.

Genes & development 20070115

The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.

The Journal of biological chemistry 20070105

Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications.

Drug metabolism and disposition: the biological fate of chemicals 20070101

Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy.

Neuro-degenerative diseases 20070101

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

PloS one 20070101

Mechanisms of Legionella pneumophila-induced interleukin-8 expression in human lung epithelial cells.

BMC microbiology 20070101

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Current medicinal chemistry 20070101

Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.

Journal of medicinal chemistry 20061228

The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.

Journal of neurochemistry 20061201

The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.

Experimental hematology 20061201

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Endocrine-related cancer 20061201

Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.

Cancer research 20061115

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20061115

Induction of multiple heat shock proteins and neuroprotection in a primary culture model of familial amyotrophic lateral sclerosis.

Neurobiology of disease 20061101

MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Molecular cancer research : MCR 20061101

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

Cancer research 20060915

Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.

Cell death and differentiation 20060901

Synthesis of a red-shifted fluorescence polarization probe for Hsp90.

Bioorganic & medicinal chemistry letters 20060901

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.

Journal of molecular medicine (Berlin, Germany) 20060801

Current and future management of GIST.

Clinical advances in hematology & oncology : H&O 20060801

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

Journal of medicinal chemistry 20060727

17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation.

Oncogene 20060713

Synthesis of Hsp90 dimerization modulators.

Bioorganic & medicinal chemistry letters 20060701

Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.

Leukemia & lymphoma 20060701

[Enhancement of HER-2 degradation by carbamazepine in breast cancer SKBR-3 cell line].

Zhonghua zhong liu za zhi [Chinese journal of oncology] 20060701

The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?

International journal of cancer 20060601

Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid.

The Journal of clinical endocrinology and metabolism 20060601

Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.

Biochemistry 20060502

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.

Leukemia research 20060501

4-Amino derivatives of the Hsp90 inhibitor CCT018159.

Bioorganic & medicinal chemistry letters 20060501

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.

Molecular carcinogenesis 20060501

Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20060501

Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

Molecular cancer therapeutics 20060501

Identification of new biomarkers for clinical trials of Hsp90 inhibitors.

Molecular cancer therapeutics 20060501

Identification of genes involved in the sensitivity to antitumour drug 17-allylamino,17-demethoxygeldanamycin (17AAG).

Molecular bioSystems 20060501

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Immunology letters 20060415

Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.

Cancer research 20060415

Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.

Leukemia 20060401

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060401

Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines.

Journal of cancer research and clinical oncology 20060301

Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis.

Molecular cancer therapeutics 20060301

Antimyeloma activity of heat shock protein-90 inhibition.

Blood 20060201

Heat shock protein 90 is an essential molecular chaperone for nuclear transport of glucocorticoid receptor beta.

Investigative ophthalmology & visual science 20060201

17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.

Cancer research 20060115

Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.

Molecular carcinogenesis 20060101

Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells.

Molecular cancer therapeutics 20060101

Hsp90 inhibitors in the clinic.

Handbook of experimental pharmacology 20060101

Stimulation of proteasome activity as a therapeutic target in schizophrenia: possible usefulness of 17-allylamino-demethoxygeldanamycin.

Medical hypotheses 20060101

Effect of the Hsp90 modulators on the heat-shock response in eukaryotic cells.

Folia microbiologica 20060101

Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.

Anticancer research 20060101

In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.

Anticancer research 20060101

Inhibitors of the HSP90 molecular chaperone: current status.

Advances in cancer research 20060101

In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin in rats.

Toxicology in vitro : an international journal published in association with BIBRA 20051201

Structure-based discovery of a new class of Hsp90 inhibitors.

Bioorganic & medicinal chemistry letters 20051201

17-AAG: mechanisms of antitumour activity.

Expert opinion on investigational drugs 20051201

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.

Cancer research 20051201

Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors.

Cancer research 20051201

Heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the radiation response of tumor cells grown as monolayer cultures and spheroids by inducing apoptosis.

Cancer science 20051201

Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.

Cancer research 20051115

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.

Cancer research 20051101

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.

Blood 20051001

In vitro detection of differential and cell-specific hepatobiliary toxicity induced by geldanamycin and 17-allylaminogeldanamycin using dog liver slices.

Toxicological sciences : an official journal of the Society of Toxicology 20051001

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.

Nature medicine 20051001

Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.

Clinical cancer research : an official journal of the American Association for Cancer Research 20051001

Targeting toxic proteins for turnover.

Nature medicine 20051001

Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.

Leukemia 20050901

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

Molecular cancer therapeutics 20050901

A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.

Clinical prostate cancer 20050901

Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation.

Bioorganic & medicinal chemistry 20050815

17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines.

Biochemical pharmacology 20050815

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.

Cancer chemotherapy and pharmacology 20050801

Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050801

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Blood 20050701

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.

Leukemia 20050701

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.

Leukemia 20050701

Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism.

Acta biochimica et biophysica Sinica 20050701

Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design.

Journal of medicinal chemistry 20050630

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050620

The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.

Cancer research 20050601

Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.

Assay and drug development technologies 20050601

Heat shock proteins and acute leukemias.

Hematology (Amsterdam, Netherlands) 20050601

Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050515

Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention.

Leukemia 20050501

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050501

Rational design of shepherdin, a novel anticancer agent.

Cancer cell 20050501

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.

Molecular pharmacology 20050401

Production of 8-demethylgeldanamycin and 4,5-epoxy-8-demethylgeldanamycin from a recombinant strain of Streptomyces hygroscopicus.

Journal of natural products 20050401

Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.

Future oncology (London, England) 20050401

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050320

Population pharmacokinetic analysis of 17-(allylamino)-17-demethoxygeldanamycin (17AAG) in adult patients with advanced malignancies.

Cancer chemotherapy and pharmacology 20050301

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.

Pediatric research 20050301

The geldanamycin derivative 17-AAG decreases VEGF secretion and leukemia growth support by trisomy 8 myelodysplastic syndrome bone marrow stromal cells.

Pediatric hematology and oncology 20050301

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050220

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

Blood 20050215

17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types.

Gynecologic oncology 20050201

Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase.

Arteriosclerosis, thrombosis, and vascular biology 20041201

Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells.

The Journal of biological chemistry 20041015

Hsp90: an emerging target for breast cancer therapy.

Anti-cancer drugs 20040801

Altered Hsp90 function in cancer: a unique therapeutic opportunity.

Molecular cancer therapeutics 20040801

[Heat shock protein 90: novel target for cancer therapy].

Ai zheng = Aizheng = Chinese journal of cancer 20040801

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040715

Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.

Nature biotechnology 20040601

An image worth a thousand lives?

Nature biotechnology 20040601

Therapeutic and diagnostic implications of Hsp90 activation.

Trends in molecular medicine 20040601

17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels.

The Journal of clinical endocrinology and metabolism 20040601

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

Cancer research 20040515

Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.

Cancer research 20040501

Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.

Molecular cancer therapeutics 20040501

Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.

Oncology (Williston Park, N.Y.) 20040501

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.

Cancer letters 20040408

17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.

Anti-cancer drugs 20040401

17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.

Blood 20040201

Altered states: selectively drugging the Hsp90 cancer chaperone.

Trends in molecular medicine 20040201

Protein chaperones as anticancer therapy targets.

Clinical advances in hematology & oncology : H&O 20040201

Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures.

Bioorganic & medicinal chemistry letters 20040119

Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.

Molecular pharmacology 20040101

Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.

Cancer research 20040101

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.

The Journal of biological chemistry 20031226

Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.

Cancer research 20031215

Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.

Cancer research 20031215

Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.

Cancer research 20031201

Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.

Cancer research 20031201

Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.

Journal of the National Cancer Institute 20031105

Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031015

Overview: translating Hsp90 biology into Hsp90 drugs.

Current cancer drug targets 20031001

Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

Current cancer drug targets 20031001

The clinical applications of heat shock protein inhibitors in cancer - present and future.

Current cancer drug targets 20031001

FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031001

Hsp90 as a therapeutic target in prostate cancer.

Seminars in oncology 20031001

Cancer: the rules of attraction.

Nature 20030925

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Nature 20030925

Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.

Blood 20030901

Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization.

Clinical cancer research : an official journal of the American Association for Cancer Research 20030901

Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.

Cancer chemotherapy and pharmacology 20030801

The Hsp90 chaperone complex as a novel target for cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology 20030801

Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.

The Journal of biological chemistry 20030704

Regulation of 17-AAG-induced apoptosis: role of Bcl-2, Bcl-XL, and Bax downstream of 17-AAG-mediated down-regulation of Akt, Raf-1, and Src kinases.

Blood 20030701

Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction.

Cancer research 20030615

Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice.

Journal of pharmacokinetics and pharmacodynamics 20030601

Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.

Current medicinal chemistry 20030501

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

Cancer research 20030501

Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.

British journal of haematology 20030501

Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.

Carcinogenesis 20030501

ErbB2 degradation mediated by the co-chaperone protein CHIP.

The Journal of biological chemistry 20030418

17AAG: low target binding affinity and potent cell activity--finding an explanation.

Molecular cancer therapeutics 20030201

Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics.

Molecular cancer therapeutics 20030201

Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.

Gene 20030102

[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20030101

The role of functional and molecular imaging in cancer drug discovery and development.

The British journal of radiology 20030101

Synthetic lethality: killing cancer with cancer.

Journal of the National Cancer Institute 20021120

Challenges of PK/PD measurements in modern drug development.

European journal of cancer (Oxford, England : 1990) 20021101

Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.

Cancer research 20021015

Heat shock protein and proteasome targeting agents.

Hematology/oncology clinics of North America 20021001

Heat shock protein inhibitor shows antitumor activity.

Journal of the National Cancer Institute 20020821

Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

Cancer research 20020601

Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020501

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.

Cancer research 20020301

Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis.

Journal of neuroscience research 20020215

Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.

Oncogene 20020214

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Expert opinion on biological therapy 20020101

Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin. Cancer Res., 7: 2228-2236, 2001.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010801

Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Cancer research 20010515

Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.

Cancer research 20010515

Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography.

Journal of chromatography. B, Biomedical sciences and applications 20010505

LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.

Bioorganic & medicinal chemistry letters 20010409

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.

Cancer research 20010401

Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.

Cancer chemotherapy and pharmacology 20010401

Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.

British journal of cancer 20010301

Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.

Cancer research 20010301

75747-14-7 | 17-AAG

Product Description

Properties

Literature

Related Products

Featured Products